Investigational New Drugs

, Volume 27, Issue 5, pp 453–460

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors

  • Sharon L. Sanborn
  • Joseph Gibbons
  • Smitha Krishnamurthi
  • Joanna M. Brell
  • Afshin Dowlati
  • Joseph A. Bokar
  • Charles Nock
  • Nancy Horvath
  • Jacob Bako
  • Scot C. Remick
  • Matthew M. Cooney
PHASE I STUDIES

DOI: 10.1007/s10637-008-9200-x

Cite this article as:
Sanborn, S.L., Gibbons, J., Krishnamurthi, S. et al. Invest New Drugs (2009) 27: 453. doi:10.1007/s10637-008-9200-x

Summary

Purpose Cytotoxic and anti-angiogenic drugs are efficacious in malignancies. This trial was undertaken to evaluate the toxicity of a novel regimen combining docetaxel and lenalidomide. Patients and methods Patients with advanced solid tumors were eligible. Docetaxel was administered on day 1, and lenalidomide was given on days 1–14 of each 21-day cycle. Since significant myelosuppression occurred, pegfilgrastim was added on day 2. Dose limiting toxicity (DLT) was defined as ≥grade 3 non-hematologic toxicity, grade 4 neutropenia with fever, or grade 4 anemia or thrombocytopenia. Results Thirty-three patients were enrolled. DLTs included neutropenia, nausea/vomiting, and dyspnea. Of the evaluable patients, 69% had stable disease, and 3% had partial response. Conclusions This regimen was well tolerated and provided stable disease in the majority of advanced cancer patients. The recommended phase II dosing is docetaxel 75 mg/m2 on day 1, lenalidomide 25 mg on days 1–14, and pegfilgrastim 6 mg on day 2, given every 3 weeks.

Keywords

DocetaxelLenalidomidePhase IAnti-angiogenic

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Sharon L. Sanborn
    • 1
  • Joseph Gibbons
    • 2
  • Smitha Krishnamurthi
    • 2
  • Joanna M. Brell
    • 2
  • Afshin Dowlati
    • 2
  • Joseph A. Bokar
    • 2
  • Charles Nock
    • 2
  • Nancy Horvath
    • 2
  • Jacob Bako
    • 2
  • Scot C. Remick
    • 3
  • Matthew M. Cooney
    • 2
  1. 1.Division of Hematology and Oncology, MetroHealth Medical CenterCase Western Reserve UniversityClevelandUSA
  2. 2.Division of Hematology and OncologyUniversity Hospitals Case Medical Center, Case Comprehensive Cancer CenterClevelandUSA
  3. 3.Mary Babb Randolph Cancer CenterWest Virginia UniversityMorgantownUSA